Your new post is loading...
Affimed develops TandAbs and Trispecific Abs for substantially increasing the efficacy and extend the therapeutic window by three proprietary platforms
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Scoop.it!
Via Krishan Maggon
Early stage mab company, lead product AFM 13 for HL in Phase II trials.